Purpose: To report the clinical outcome of the treatment of dry eyes using 0.03% tacrolimus eye drops (olive oil + tacrolimus 0.03%) (Ophthalmos, Sao Paulo, Brazil). Methods: Sixteen eyes of 8 patients with Sjogren syndrome dry eyes (age, 51.13 +/- 9.45 years) were enrolled in this study (prospective noncontrolled interventional case series). Patients were instructed to use topical 0.03% tacrolimus eye drops twice a day (every 12 hours) in the lower conjunctival sac. Schirmer I test, break-up time, corneal fluorescein, and rose bengal staining score were performed in all patients 1 day before, and 14, 28, and 90 days after treatment with 0.03% tacrolimus eye drops. Results: The average fluorescein staining and rose bengal staining scores im...
Dry-eye disease (DED) is a highly prevalent ocular condition in patients with Sjögren syndrome (SS) ...
Alejandro J Aguilar, Maria I Marquez, Paula A Albera, Jorge L Tredicce, Alejandro Berra Universidad...
Background: To assess the clinical efficacy, tolerability and safety of a new-generation ophthalmic ...
Purpose: To report the clinical outcome of the treatment of dry eyes using 0.03% tacrolimus eye drop...
Purpose: evaluation of the efficacy of the drug Tealose® in the therapy of cornea inflammatory disea...
Purpose: Evaluation of 0.3% cortisol phosphate eye drops in hyaluronic acid vehicle in the treatment...
PURPOSE: To evaluate the efficacy of topical cyclosporine A 0.05% (Restasis) in the treatment of dry...
<p><strong>Purpose</strong>: to investigate therapeutic effectiveness of several new pharmacotherape...
Purpose: To assess the six-month therapeutic profiles of lipid and non-lipid-based artificial tear s...
Purpose: To assess the six-month therapeutic profiles of lipid and non-lipid-based artificial tear s...
Purpose: To assess the six-month therapeutic profiles of lipid and non-lipid-based artificial tear s...
PubMed ID: 24566903Background: To evaluate the efficacy of autologous serum (AS) eye drops for the s...
Purpose: To assess the six-month therapeutic profiles of lipid and non-lipid-based artificial tear s...
Purpose: To assess the six-month therapeutic profiles of lipid and non-lipid-based artificial tear s...
Dry eye syndrome is frequently observed in patients with primary open-angle glaucoma with prolonged ...
Dry-eye disease (DED) is a highly prevalent ocular condition in patients with Sjögren syndrome (SS) ...
Alejandro J Aguilar, Maria I Marquez, Paula A Albera, Jorge L Tredicce, Alejandro Berra Universidad...
Background: To assess the clinical efficacy, tolerability and safety of a new-generation ophthalmic ...
Purpose: To report the clinical outcome of the treatment of dry eyes using 0.03% tacrolimus eye drop...
Purpose: evaluation of the efficacy of the drug Tealose® in the therapy of cornea inflammatory disea...
Purpose: Evaluation of 0.3% cortisol phosphate eye drops in hyaluronic acid vehicle in the treatment...
PURPOSE: To evaluate the efficacy of topical cyclosporine A 0.05% (Restasis) in the treatment of dry...
<p><strong>Purpose</strong>: to investigate therapeutic effectiveness of several new pharmacotherape...
Purpose: To assess the six-month therapeutic profiles of lipid and non-lipid-based artificial tear s...
Purpose: To assess the six-month therapeutic profiles of lipid and non-lipid-based artificial tear s...
Purpose: To assess the six-month therapeutic profiles of lipid and non-lipid-based artificial tear s...
PubMed ID: 24566903Background: To evaluate the efficacy of autologous serum (AS) eye drops for the s...
Purpose: To assess the six-month therapeutic profiles of lipid and non-lipid-based artificial tear s...
Purpose: To assess the six-month therapeutic profiles of lipid and non-lipid-based artificial tear s...
Dry eye syndrome is frequently observed in patients with primary open-angle glaucoma with prolonged ...
Dry-eye disease (DED) is a highly prevalent ocular condition in patients with Sjögren syndrome (SS) ...
Alejandro J Aguilar, Maria I Marquez, Paula A Albera, Jorge L Tredicce, Alejandro Berra Universidad...
Background: To assess the clinical efficacy, tolerability and safety of a new-generation ophthalmic ...